Sunshine Biopharma announced today that it has completed the pharmacokinetics studies in live rats for its lead anti-tumor compound, Adva-27a. Pharmacokinetics studies deal with the determination of the fate of substances administered to a living organism; more specifically, pharmacokinetics studies deal with the study of the mechanisms of absorption and distribution of an administered drug and the rate at which a drug action begins and the duration of the effect.
Sunshine Biopharma's recently completed pharmacokinetics studies analyzed the properties of Adva-27a and Etoposide in the plasma of live rats under a single intravenous bolus injection. While both had a mean terminal phase plasma half-life of around one hour, Adva-27a produced a 2.8-fold higher plasma initial concentration (C0 = 8779 ng/mL) than Etoposide (C0 = 3183 ng/mL). Additionally, the area under the plasma concentration-versus-time curve for Adva-27a (AUCinf - 2211 hr-ng/mL) was 2.4-times higher than that of Etoposide (AUCinf = 933 hr-ng/mL). Adva-27a, moreover, had a significantly lower plasma clearance rate (CL = 19.0 mL/min/kg) compared to Etoposide (CL = 44.7 mL/min/kg).
The results indicate that Adva-27a's pharmacokinetics profile is significantly better than Etoposide's. This finding, coupled with Sunshine Biopharma's prior observation that Adva-27a can overcome multidrug resistance in breast cancer cells, further confirms the uniqueness of Adva-27a as an anti-cancer compound.
The company is presently conducting the next sequence of steps in its development of Adva-27a, which includes GMP manufacturing, IND-enabling studies, and filing an IND application, followed by phase I clinical trials in humans.
Sunshine Biopharma is a development-stage pharmaceutical company focused on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
For more information, visit the company's Web site at sunshinebiopharma.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net